Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Global regulators and industry execs to gather in US and Germany to talk device regulation

This article was originally published in RAJ Devices

  • Peter Rixon

Executive Summary

Compliance, approvals, inspections and many other burning issues will be on the agenda of a US conference that takes place in early May.

You may also be interested in...



US: The sun shines in on industry-doctor relationships

The US healthcare reform proposals signed into law on 23 March include requirements on medical device companies to reveal payments or gifts they make to doctors. Peter Rixon takes a closer look at what the reforms’ “sunshine” provisions actually mean

Global regulators/industry to gather in US and Germany to talk device regulation

Compliance, approvals, inspections and many other burning issues will be on the agenda of a US conference that takes place in the coming weeks.

Global regulators and industry execs to gather in US and Germany to talk device regulation

Compliance, approvals, inspections and many other burning issues will be on the agenda of a US conference that takes place in early May.

Table

View full table

Tags:
Latest Headlines

Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use

With One Launch Under Way, SpringWorks Ramps Up For A Second

Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar

Key Activist Investor Throws Shade At Novavax Over COVID-19 Vaccines

See All
UsernamePublicRestriction

Register

SC096002

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By